3M vs Stryker
MMM and SYK side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MMM and SYK compare
Stryker is the larger company, worth 1.2 times as much as 3M ($112B against $89.9B).
On earnings, 3M is cheaper: it trades at 31.0× trailing earnings, against 31.1× for Stryker.
Stryker grew revenue faster over the last twelve months (7.9% versus 2.3% for 3M).
Stryker keeps more of each dollar of sales as profit, with a net margin of 13.8% compared with 11.9% at 3M.
Both pay dividends: 3M yields 1.8% and Stryker 1.2%.
Stryker scores higher on the StockData Score (19 against 13 for 3M), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MMM | SYK |
|---|---|---|
| Size and price | ||
| Market cap | $89.9B | $112B |
| Share price | $174.34 | $291.86 |
| Change, 1 year | 5.9% | −21.0% |
| Change, 5 years | −4.1% | 5.7% |
| Beta (5Y) | 1.03 | 0.85 |
| Employees | 61K | 56K |
| StockData Score | ||
| Total score | 13 | 19 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 1 | 5 (better) |
| Performance score | 5 (better) | 3 |
| Health score | 4 | 4 |
| Dividend score | 3 | 3 |
| Valuation | ||
| P/E | 31.0× (better) | 31.1× |
| P/S | 3.6× (better) | 4.3× |
| P/B | 30.5× | – |
| EV/EBITDA | 16.6× (better) | 17.5× |
| P/FCF | 22.6× (better) | 24.5× |
| PEG | – | 2.87 |
| FCF yield | 4.4% (better) | 4.1% |
| Fair value | $124.05 | $381.63 |
| Margin of safety | −40.5% | 23.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 2.3% | 7.9% (better) |
| Revenue growth, 5Y average | −5.0% | 11.8% (better) |
| Net income growth (TTM) | −23.9% | 23.1% (better) |
| EPS growth (TTM) | −21.7% | 23.4% (better) |
| EPS growth, 5Y average | −8.5% | 14.9% (better) |
| Profitability | ||
| Gross margin | 39.4% | 65.3% (better) |
| Operating margin | 18.4% | 20.7% (better) |
| Net margin | 11.9% | 13.8% (better) |
| FCF margin | 15.8% | 17.4% (better) |
| Return on equity | 82.8% | – |
| Return on invested capital | 27.1% | – |
| Financial health | ||
| Debt / equity | 4.25 | – |
| Net debt / EBITDA | 1.60 (better) | 1.65 |
| Interest coverage | 5.3× | 9.3× (better) |
| Current ratio | 1.24 | 2.18 (better) |
| Altman Z-score | 4.49 | 4.58 (better) |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Dividend yield | 1.8% (better) | 1.2% |
| Payout ratio | 53.0% | 36.8% |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | −13.1% | – |
| Buyback yield | 4.5% | – |
| Shareholder yield | 6.2% (better) | 1.2% |
| Ownership | ||
| Held by institutions | 75.1% | 80.2% |
| Held by insiders | 0.09% | 4.1% |
| Insider net buying, 12 months | −$21.3M (better) | −$586M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 1.9% | 1.6% |
Go deeper
- MMM stock overview
- MMM income statement
- MMM valuation and score
- SYK stock overview
- SYK income statement
- SYK valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.